Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06698302 · ClinicalTrials.gov registry record

Validation of COMPAT-SF Spanish Translation

A clinical trial of Chronic Pancreatitis, sponsored by Methodist Health System.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT06698302 is a study of Chronic Pancreatitis that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 100 participants, below the 687-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06698302, a study of Chronic Pancreatitis, is actively recruiting participants, sponsored by Methodist Health System.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

Prospective translation validation pilot study that will collect data from Spanish-speaking CP patients seen at Methodist Dallas Medical Center (MDMC) beginning June 2024 through July 2027, in order to validate a Spanish-translated COMPAT-SF instrument.

Conditions Studied

Interventions

  • BEHAVIORAL Questionnaires

Study Locations (1)

Texas

  • Methodist Dallas Medical Center- Clinical Research Institute - Dallas

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-09-13
Est. Completion 2026-09-13

Sponsor

Methodist Health System

125 total trials

What the Registry Record Tells You About NCT06698302

The ClinicalTrials.gov registry entry for NCT06698302 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 687-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (85% lower). The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.

NCT06698302 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06698302 about?

NCT06698302 is a clinical study titled "Validation of COMPAT-SF Spanish Translation". Prospective translation validation pilot study that will collect data from Spanish-speaking CP patients seen at Methodist Dallas Medical Center (MDMC) beginning June 2024 through July 2027, in order to validate a Spanish-translated COMPAT-SF instrument.

What is the current status of trial NCT06698302?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-09-13. Estimated completion is 2026-09-13.

What conditions does trial NCT06698302 study?

This clinical trial studies the following conditions: Chronic Pancreatitis.

What interventions are being tested in trial NCT06698302?

The interventions under investigation include: Questionnaires (BEHAVIORAL).

Who is sponsoring clinical trial NCT06698302?

This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06698302 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.